Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Tirzepatide consistently reduced waist circumference in clinical trials, with mean reductions of approximately 14-16 cm (5.5-6.3 inches) at the 15 mg dose in SURMOUNT-1
Why This Matters More For Women in Mid-Life Women in menopause and beyond face a specific metabolic landscape: declining estrogen, increasing insulin resistance, accelerating visceral fat accumulation, and anabolic resistance
Obesity is associated with reduced testosterone levels, erectile dysfunction, and decreased sperm quality
Thyroid tumor risk: Tirzepatide carries a black box warning based on rat studies showing dose-dependent thyroid C-cell tumor development
Research indicates that reducing NNMT activity with 5-amino-1MQ alters metabolic processes, promotes changes in adipocyte function, and modulates muscle and nerve physiology
Any attempt by you to assign your rights under these Terms and Conditions of Use without the permission of MTA shall be void
US$ 27.05
US$ 20.95
US$ 24.55
US$ 24.81
